Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2008

01.12.2008 | Research Article

Pharmacist intervention reduces gastropathy risk in patients using NSAIDs

verfasst von: Victoria Ibañez-Cuevas, Eduardo Lopez-Briz, M. Teresa Guardiola-Chorro, On behalf of the NSAID induced Gastropathy Prevention Programme Group

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2008

Einloggen, um Zugang zu erhalten

Abstract

Objective To establish a detection and intervention strategy in order to reduce the number of non-steroidal anti-inflammatory drug (NSAIDs) users at risk of gastropathy from receiving either inadequate or no gastroprotection. Setting Community Pharmacies in Valencia, Spain. Method Prospective longitudinal intervention study without control group carried out by 79 Community Pharmacies. Patients over 18 who asked for any systemic NSAID were interviewed according to standard procedure. Pharmacist intervention was carried out when a patient at risk of serious NSAID-induced gastrointestinal complications due to inadequate or no gastric protection was identified. The doctor responsible was informed in order to then be able to assess the need to prescribe gastroprotection or change it if inadequate. In the case of over-the-counter (OTC) drugs, pharmacist intervention mainly involved replacing NSAIDs for safer medications. Main outcome measure Firstly, the number of patients who had no prescribed gastroprotection or inadequate gastroprotection was determined. Pharmacist intervention then brought about changes in pharmacotherapy in this situation. Results Of the 6,965 patients who asked for NSAIDs during the study period, 3,054 (43.9%) presented NSAID gastropathy risk factors. 35.6% of the latter (1,089) were not prescribed gastroprotection or were prescribed inadequate gastroprotection. Pharmacist intervention was carried out in 1,075 of these cases. On 391 occasions such risk situations were reported to doctors, who accepted pharmacist intervention on 309 occasions (79.0%) and then either prescribed gastroprotection (77% of cases); changed it (13.9%); withdrew the NSAID (5.8%) or substituted it (3.2%). 235 Pharmacist interventions took place when dispensing OTC NSAIDs. Conclusion Our strategy allowed us to identify a large number of patients who asked for NSAIDs in Community Pharmacies and who were at risk of NSAID gastropathy, as they received either inadequate gastroprotection or no gastroprotection whatsoever. Moreover, the pharmacist intervention carried out has reduced the number of these risk situations.
Literatur
1.
Zurück zum Zitat Ballina J, Carmona L, Laffon A. y Grupo de Estudio EPISER El impacto del consumo de AINE en la población general. Resultados del estudio EPISER (Impact of NSAID use in general population. Results of EPISER study). Rev Esp Reumatol. 2002;29:337–422. Ballina J, Carmona L, Laffon A. y Grupo de Estudio EPISER El impacto del consumo de AINE en la población general. Resultados del estudio EPISER (Impact of NSAID use in general population. Results of EPISER study). Rev Esp Reumatol. 2002;29:337–422.
2.
Zurück zum Zitat De Abajo F, García del Pozo J, del Pino A. Evolución de la utilización de antiinflamatorios no esteroideos en España desde 1990 hasta 2003 (Evolution of non-steroidal antiinflammatory drugs utilisation in Spain from 1990 to 2003). Aten Primaria. 2005;36:424–33. doi:10.1157/13081056.PubMedCrossRef De Abajo F, García del Pozo J, del Pino A. Evolución de la utilización de antiinflamatorios no esteroideos en España desde 1990 hasta 2003 (Evolution of non-steroidal antiinflammatory drugs utilisation in Spain from 1990 to 2003). Aten Primaria. 2005;36:424–33. doi:10.​1157/​13081056.PubMedCrossRef
5.
Zurück zum Zitat Lanas A, Pérez-Aisa MA, Fe F, Ponce J, Saperas E, Santolaria S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100:1685–93. doi:10.1111/j.1572-0241.2005.41833.x.PubMedCrossRef Lanas A, Pérez-Aisa MA, Fe F, Ponce J, Saperas E, Santolaria S, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol. 2005;100:1685–93. doi:10.​1111/​j.​1572-0241.​2005.​41833.​x.PubMedCrossRef
8.
Zurück zum Zitat MacRae F, MacCollK ML, Williams D. Strategies against NSAID-induced gastrointestinal side effects: part 1. Pharm J. 2004;272:187–9. MacRae F, MacCollK ML, Williams D. Strategies against NSAID-induced gastrointestinal side effects: part 1. Pharm J. 2004;272:187–9.
9.
Zurück zum Zitat Rostom A, Dube C, Jolicoeur E, Boucher M, Joyce J. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment 2004 Technology overview n. 12. http://cadth.ca/media/pdf/168_gastroprotective_tr_e.pdf. Accessed 20 May 2005. Rostom A, Dube C, Jolicoeur E, Boucher M, Joyce J. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment 2004 Technology overview n. 12. http://​cadth.​ca/​media/​pdf/​168_​gastroprotective​_​tr_​e.​pdf. Accessed 20 May 2005.
10.
Zurück zum Zitat Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD002296. doi:10.1002/14651858.CD002296. Rostom A, Dube C, Wells G, Tugwell P, Welch V, Jolicoeur E, et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database of Systematic Reviews 2002, Issue 4. Art. No.: CD002296. doi:10.​1002/​14651858.​CD002296.
11.
Zurück zum Zitat Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology. 2003;42(suppl 3):iii23–31. doi:10.1093/rheumatology/keg495.PubMed Sturkenboom MCJM, Burke TA, Dieleman JP, Tangelder MJD, Lee F, Goldstein JL. Underutilization of preventive strategies in patients receiving NSAIDs. Rheumatology. 2003;42(suppl 3):iii23–31. doi:10.​1093/​rheumatology/​keg495.PubMed
12.
Zurück zum Zitat Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2002;46:2195–200. doi:10.1002/art.10425.PubMedCrossRef Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2002;46:2195–200. doi:10.​1002/​art.​10425.PubMedCrossRef
13.
Zurück zum Zitat Chumney EC, Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. Pharm Pract. 2006;4:103–9. Chumney EC, Robinson LC. The effects of pharmacist interventions on patients with polypharmacy. Pharm Pract. 2006;4:103–9.
14.
Zurück zum Zitat Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother. 2005;39:319–28. doi:10.1345/aph.1E027.PubMedCrossRef Van Wijk BLG, Klungel OH, Heerdink ER, de Boer A. Effectiveness of interventions by community pharmacists to improve patient adherence to chronic medication: a systematic review. Ann Pharmacother. 2005;39:319–28. doi:10.​1345/​aph.​1E027.PubMedCrossRef
15.
Zurück zum Zitat Carter BL, Malone DC, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Impact of managed pharmaceutical care on resource utilization and outcomes in veterans affairs medical centers. Interpreting the findings of the IMPROVE study. Am J Health Syst Pharm. 2001;58:1330–7.PubMed Carter BL, Malone DC, Billups SJ, Valuck RJ, Barnette DJ, Sintek CD, et al. Impact of managed pharmaceutical care on resource utilization and outcomes in veterans affairs medical centers. Interpreting the findings of the IMPROVE study. Am J Health Syst Pharm. 2001;58:1330–7.PubMed
16.
Zurück zum Zitat M.I.Colegio Oficial de Farmacéuticos de Valencia. Estudio sobre la distribución geográfica de las oficinas de farmacia de la Unión Europea (Study on geographical distribution of community pharmacies in European Union). Cuad Farm. 2008;200:15–39. M.I.Colegio Oficial de Farmacéuticos de Valencia. Estudio sobre la distribución geográfica de las oficinas de farmacia de la Unión Europea (Study on geographical distribution of community pharmacies in European Union). Cuad Farm. 2008;200:15–39.
19.
Zurück zum Zitat Orden de 17 de septiembre de 1982 por la que se desarrolla el Real Decreto 2730/1981 sobre el Registro de Especialidades Farmacéuticas Publicitarias. BOE n. 233 de 29-9-1982. Orden de 17 de septiembre de 1982 por la que se desarrolla el Real Decreto 2730/1981 sobre el Registro de Especialidades Farmacéuticas Publicitarias. BOE n. 233 de 29-9-1982.
20.
Zurück zum Zitat Gil A, Vargas E, Mateo C, et al. Profilaxis de la gastropatía por AINE en un centro de Atención primaria: Adecuación del tratamiento y consecuencias económicas (Prophylaxis of NSAID gastropathy in a Primary Care Center: Treatment adequacy and economic consequences). Aten Farm. 2002;4:19–24. Gil A, Vargas E, Mateo C, et al. Profilaxis de la gastropatía por AINE en un centro de Atención primaria: Adecuación del tratamiento y consecuencias económicas (Prophylaxis of NSAID gastropathy in a Primary Care Center: Treatment adequacy and economic consequences). Aten Farm. 2002;4:19–24.
21.
Zurück zum Zitat De Dios R, del Valle A, Hernández Sánchez A, Franco Vidal A, González Rubio Y, Romera Fernández I. Prescripción de antiinflamatorios no esteroideos y protectores gástricos en urgencias (Prescription of nonsteroidal antiinflammatory drugs and gastroprotectors in Emergency Room). Aten Primaria. 2003;31:500–5. doi:10.1157/13047732.CrossRef De Dios R, del Valle A, Hernández Sánchez A, Franco Vidal A, González Rubio Y, Romera Fernández I. Prescripción de antiinflamatorios no esteroideos y protectores gástricos en urgencias (Prescription of nonsteroidal antiinflammatory drugs and gastroprotectors in Emergency Room). Aten Primaria. 2003;31:500–5. doi:10.​1157/​13047732.CrossRef
22.
Zurück zum Zitat Arboleya LR, de la Figuera E, García MS, Aragón B. y Grupo de Estudio VICOXX. Tratamiento sintomático de la artrosis: patrón de utilización de antiinflamatorios no esteroideos en los centros de salud españoles (Symptomatic treatment of arthrosis: non-steroidal antiinflammatory drugs utilisation patterns at Spanish Primary Care). Rev Esp Reumatol. 2002;29:300–7. Arboleya LR, de la Figuera E, García MS, Aragón B. y Grupo de Estudio VICOXX. Tratamiento sintomático de la artrosis: patrón de utilización de antiinflamatorios no esteroideos en los centros de salud españoles (Symptomatic treatment of arthrosis: non-steroidal antiinflammatory drugs utilisation patterns at Spanish Primary Care). Rev Esp Reumatol. 2002;29:300–7.
23.
Zurück zum Zitat Carvajal A, Martín-Arias LH, Vega E, García Sánchez JA, Martín Rodríguez I, García Ortega P, et al. Gastroprotection during the administration of nonsteroidal anti-inflammatory drugs. A drug utilization study. Eur J Clin Pharmacol. 2004;60:439–44. doi:10.1007/s00228-004-0782-8.PubMedCrossRef Carvajal A, Martín-Arias LH, Vega E, García Sánchez JA, Martín Rodríguez I, García Ortega P, et al. Gastroprotection during the administration of nonsteroidal anti-inflammatory drugs. A drug utilization study. Eur J Clin Pharmacol. 2004;60:439–44. doi:10.​1007/​s00228-004-0782-8.PubMedCrossRef
26.
Zurück zum Zitat Vargas E, Cabrera L, Morón A, García M, Soto J, Guadarrama I. Evaluación del coste hospitalario derivado del diagnóstico y tratamiento de las hemorragias digestivas en pacientes tomadores de antiinflamatorios no esteroideos (Evaluation of hospital costs leading from diagnostic and treatment of digestive bleedings in patients who use non-steroidal antiinflammatory drugs). Rev Esp Enf Ap Dig. 2001;93:390–7. Vargas E, Cabrera L, Morón A, García M, Soto J, Guadarrama I. Evaluación del coste hospitalario derivado del diagnóstico y tratamiento de las hemorragias digestivas en pacientes tomadores de antiinflamatorios no esteroideos (Evaluation of hospital costs leading from diagnostic and treatment of digestive bleedings in patients who use non-steroidal antiinflammatory drugs). Rev Esp Enf Ap Dig. 2001;93:390–7.
27.
30.
31.
Zurück zum Zitat Baos Vicente V. Estrategias para reducir los riesgos de la automedicación (Strategies to reduce self-medication risks). Inf Ter Sist Nac Salud. 2000;24:147–52. Baos Vicente V. Estrategias para reducir los riesgos de la automedicación (Strategies to reduce self-medication risks). Inf Ter Sist Nac Salud. 2000;24:147–52.
33.
Zurück zum Zitat Marco JL, Boscá B, Real M, et al. Ingresos hospitalarios por hemorragia digestiva alta por antiinflamatorios no esteroídicos (Hospital admission for upper digestive bleeding non-steroidal anti-inflammatory drugs-induced). Seguim Farmacoter. 2004;2:217–27. Marco JL, Boscá B, Real M, et al. Ingresos hospitalarios por hemorragia digestiva alta por antiinflamatorios no esteroídicos (Hospital admission for upper digestive bleeding non-steroidal anti-inflammatory drugs-induced). Seguim Farmacoter. 2004;2:217–27.
34.
Zurück zum Zitat Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomised trial of antiplatelet therapy por prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71–86. doi:10.1136/bmj.324.7336.S71.CrossRef Antithrombotic Trialist Collaboration. Collaborative meta-analysis of randomised trial of antiplatelet therapy por prevention of death, myocardial infarction and stroke in high risk patients. BMJ. 2002;324:71–86. doi:10.​1136/​bmj.​324.​7336.​S71.CrossRef
Metadaten
Titel
Pharmacist intervention reduces gastropathy risk in patients using NSAIDs
verfasst von
Victoria Ibañez-Cuevas
Eduardo Lopez-Briz
M. Teresa Guardiola-Chorro
On behalf of the NSAID induced Gastropathy Prevention Programme Group
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2008
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-008-9258-8

Weitere Artikel der Ausgabe 6/2008

International Journal of Clinical Pharmacy 6/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Aquatherapie bei Fibromyalgie wirksamer als Trockenübungen

03.05.2024 Fibromyalgiesyndrom Nachrichten

Bewegungs-, Dehnungs- und Entspannungsübungen im Wasser lindern die Beschwerden von Patientinnen mit Fibromyalgie besser als das Üben auf trockenem Land. Das geht aus einer spanisch-brasilianischen Vergleichsstudie hervor.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Das Risiko für Vorhofflimmern in der Bevölkerung steigt

02.05.2024 Vorhofflimmern Nachrichten

Das Risiko, im Lauf des Lebens an Vorhofflimmern zu erkranken, ist in den vergangenen 20 Jahren gestiegen: Laut dänischen Zahlen wird es drei von zehn Personen treffen. Das hat Folgen weit über die Schlaganfallgefährdung hinaus.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.